Proinflammatory Cytokines and Chemokines - But not Interferon-β - Produced in Response to HSV-2 in Primary Human Genital Epithelial Cells are Associated with Viral Replication and the Presence of the Virion Host Shutoff Protein

American Journal of Reproductive Immunology

Volumn 70, Issue 3, 2013, Pages 199-212

  Ferreira, Victor H ^a   Nazli, Aisha ^a   Mossman, Karen L ^a   Kaushic, Charu ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Cytokines; Genital epithelial cells; HSV 2; Interferon; Mucosal immunity; Viral immunology

Indexed keywords

BETA INTERFERON; CXCL2 CHEMOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; NEUTRALIZING ANTIBODY; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRION HOST SHUTOFF PROTEIN; VIRUS DNA; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; DNA EXTRACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM; FEMALE; GENITAL EPITHELIAL CELL; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN TISSUE; IMMUNOASSAY; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VERO CELL; VESICULAR STOMATITIS VIRUS; VIRION; VIRUS REPLICATION;

CYTOKINES; GENITAL EPITHELIAL CELLS; HSV-2; INTERFERON; MUCOSAL IMMUNITY; VIRAL IMMUNOLOGY;

ADULT; ANIMALS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CHEMOKINES; CYTOKINES; EPITHELIAL CELLS; FEMALE; GENITALIA, FEMALE; HERPES SIMPLEX; HERPESVIRUS 2, HUMAN; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INTERFERON-BETA; MIDDLE AGED; RIBONUCLEASES; UP-REGULATION; VERO CELLS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84881491379     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/aji.12133     Document Type: Article

References (65)

1. Looker KJ, Garnett GP, Schmid GP: An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ 2008; 86:805-812, A.
2. Nahmias AJ, Lee FK, Beckman-Nahmias S: Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl 1990; 69:19-36.
3. Smith JS, Robinson NJ: Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis 2002; 186(Suppl 1):S3-S28.
4. Wald A, Corey L: How does herpes simplex virus type 2 influence human immunodeficiency virus infection and pathogenesis? J Infect Dis 2003; 187:1509-1512.
5. Celum CL: The interaction between herpes simplex virus and human immunodeficiency virus. Herpes 2004; 11(Suppl 1):36A-45A.
6. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ: Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73-83.
7. Corey L, Wald A, Celum CL, Quinn TC: The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004; 35:435-445.
8. Langenberg AG, Corey L, Ashley RL, Leong WP, Straus SE: A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med 1999; 341:1432-1438.
9. Corey L, Adams HG, Brown ZA, Holmes KK: Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 1983; 98:958-972.
10. Schacker T, Zeh J, Hu HL, Hill E, Corey L: Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis 1998; 178:1616-1622.
11. Augenbraun M, Feldman J, Chirgwin K, Zenilman J, Clarke L, DeHovitz J, Landesman S, Minkoff H: Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women. Ann Intern Med 1995; 123:845-847.
12. Wald A, Huang ML, Carrell D, Selke S, Corey L: Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis 2003; 188:1345-1351.
13. Wira CR, Fahey JV, Sentman CL, Pioli PA, Shen L: Innate and adaptive immunity in female genital tract: cellular responses and interactions. Immunol Rev 2005; 206:306-335.
14. Wira CR, Grant-Tschudy KS, Crane-Godreau MA: Epithelial cells in the female reproductive tract: a central role as sentinels of immune protection. Am J Reprod Immunol 2005; 53:65-76.
15. Huber MT, Wisner TW, Hegde NR, Goldsmith KA, Rauch DA, Roller RJ, Krummenacher C, Eisenberg RJ, Cohen GH, Johnson DC: Herpes simplex virus with highly reduced gD levels can efficiently enter and spread between human keratinocytes. J Virol 2001; 75:10309-10318.
16. Schelhaas M, Jansen M, Haase I, Knebel-Morsdorf D: Herpes simplex virus type 1 exhibits a tropism for basal entry in polarized epithelial cells. J Gen Virol 2003; 84:2473-2484.
17. Li H, Zhang J, Kumar A, Zheng M, Atherton SS, Yu FS: Herpes simplex virus 1 infection induces the expression of proinflammatory cytokines, interferons and TLR7 in human corneal epithelial cells. Immunology 2006; 117:167-176.
18. Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A: Toll-like receptor 9-mediated recognition of herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med 2003; 198:513-520.
19. Spear PG: Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol 2004; 6:401-410.
20. Sato A, Linehan MM, Iwasaki A: Dual recognition of herpes simplex viruses by TLR2 and TLR9 in dendritic cells. Proc Natl Acad Sci U S A 2006; 103:17343-17348.
21. Huang W, Hu K, Luo S, Zhang M, Li C, Jin W, Liu Y, Griffin GE, Shattock RJ, Hu Q: Herpes simplex virus type 2 infection of human epithelial cells induces CXCL9 expression and CD4+ T cell migration via activation of p38-CCAAT/enhancer-binding protein-beta pathway. J Immunol 2012; 188:6247-6257.
22. MacDonald EM, Savoy A, Gillgrass A, Fernandez S, Smieja M, Rosenthal KL, Ashkar AA, Kaushic C: Susceptibility of human female primary genital epithelial cells to herpes simplex virus, type-2 and the effect of TLR3 ligand and sex hormones on infection. Biol Reprod 2007; 77:1049-1059.
23. Nazli A, Yao XD, Smieja M, Rosenthal KL, Ashkar AA, Kaushic C: Differential induction of innate anti-viral responses by TLR ligands against Herpes simplex virus, type 2, infection in primary genital epithelium of women. Antiviral Res 2009; 81:103-112.
24. Kropp RY, Wong T, Cormier L, Ringrose A, Burton S, Embree JE, Steben M: Neonatal herpes simplex virus infections in Canada: results of a 3-year national prospective study. Pediatrics 2006; 117:1955-1962.
25. Samady L, Costigliola E, MacCormac L, McGrath Y, Cleverley S, Lilley CE, Smith J, Latchman DS, Chain B, Coffin RS: Deletion of the virion host shutoff protein (vhs) from herpes simplex virus (HSV) relieves the viral block to dendritic cell activation: potential of vhs- HSV vectors for dendritic cell-mediated immunotherapy. J Virol 2003; 77:3768-3776.
26. Cotter CR, Kim WK, Nguyen ML, Yount JS, Lopez CB, Blaho JA, Moran TM: The virion host shutoff protein of herpes simplex virus 1 blocks the replication-independent activation of NF-kappaB in dendritic cells in the absence of type I interferon signaling. J Virol 2011; 85:12662-12672.
27. Cotter CR, Nguyen ML, Yount JS, Lopez CB, Blaho JA, Moran TM: The virion host shut-off (vhs) protein blocks a TLR-independent pathway of herpes simplex virus type 1 recognition in human and mouse dendritic cells. PLoS ONE 2010; 5:e8684.
28. Prechtel AT, Turza NM, Kobelt DJ, Eisemann JI, Coffin RS, McGrath Y, Hacker C, Ju X, Zenke M, Steinkasserer A: Infection of mature dendritic cells with herpes simplex virus type 1 dramatically reduces lymphoid chemokine-mediated migration. J Gen Virol 2005; 86:1645-1657.
29. Suzutani T, Nagamine M, Shibaki T, Ogasawara M, Yoshida I, Daikoku T, Nishiyama Y, Azuma M: The role of the UL41 gene of herpes simplex virus type 1 in evasion of non-specific host defence mechanisms during primary infection. J Gen Virol 2000; 81:1763-1771.
30. Murphy JA, Duerst RJ, Smith TJ, Morrison LA: Herpes simplex virus type 2 virion host shutoff protein regulates alpha/beta interferon but not adaptive immune responses during primary infection in vivo. J Virol 2003; 77:9337-9345.
31. Duerst RJ, Morrison LA: Herpes simplex virus 2 virion host shutoff protein interferes with type I interferon production and responsiveness. Virology 2004; 322:158-167.
32. Fakioglu E, Wilson SS, Mesquita PM, Hazrati E, Cheshenko N, Blaho JA, Herold BC: Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism. J Virol 2008; 82:9337-9344.
33. Pardoe I, Dargan D: PREPS and L-particles: a new approach to virus-like particle vaccines. Expert Rev Vaccines 2002; 1:427-432.
34. Kaushic C, Nazli A, Ferreira VH, Kafka JK: Primary human epithelial cell culture system for studying interactions between female upper genital tract and sexually transmitted viruses, HSV-2 and HIV-1. Methods 2011; 55:114-121.
35. Gillgrass AE, Fernandez SA, Rosenthal KL, Kaushic C: Estradiol regulates susceptibility following primary exposure to genital herpes simplex virus type 2, while progesterone induces inflammation. J Virol 2005; 79:3107-3116.
36. Paladino P, Cummings DT, Noyce RS, Mossman KL: The IFN-independent response to virus particle entry provides a first line of antiviral defense that is independent of TLRs and retinoic acid-inducible gene I. J Immunol 2006; 177:8008-8016.
37. Antonelli G, Simeoni E, Turriziani O, Tesoro R, Redaelli A, Roffi L, Antonelli L, Pistello M, Dianzani F: Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy. J Interferon Cytokine Res 1999; 19:243-251.
38. Farrugia J, Cann AJ: Internally controlled quantitative assays for PKR mRNA and protein from liver biopsies and other finite clinical samples. J Immunol Methods 1999; 228:59-68.
39. Nacionales DC, Kelly KM, Lee PY, Zhuang H, Li Y, Weinstein JS, Sobel E, Kuroda Y, Akaogi J, Satoh M, Reeves WH: Type I interferon production by tertiary lymphoid tissue developing in response to 2, 6, 10, 14-tetramethyl-pentadecane (pristane). Am J Pathol 2006; 168:1227-1240.
40. Ferreira VH, Nazli A, Khan G, Mian MF, Ashkar AA, Gray-Owen S, Kaul R, Kaushic C: Endometrial epithelial cell responses to coinfecting viral and bacterial pathogens in the genital tract can activate the HIV-1 LTR in an NF{kappa}B-and AP-1-dependent manner. J Infect Dis 2011; 204:299-308.
41. Dohner K, Radtke K, Schmidt S, Sodeik B: Eclipse phase of herpes simplex virus type 1 infection: efficient dynein-mediated capsid transport without the small capsid protein VP26. J Virol 2006; 80:8211-8224.
42. Decker T, Muller M, Stockinger S: The yin and yang of type I interferon activity in bacterial infection. Nat Rev Immunol 2005; 5:675-687.
43. Ank N, Paludan SR: Type III IFNs: new layers of complexity in innate antiviral immunity. BioFactors 2009; 35:82-87.
44. Platanias LC: Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005; 5:375-386.
45. Adams O, Besken K, Oberdorfer C, MacKenzie CR, Russing D, Daubener W: Inhibition of human herpes simplex virus type 2 by interferon gamma and tumor necrosis factor alpha is mediated by indoleamine 2, 3-dioxygenase. Microbes Infect 2004; 6:806-812.
46. LeBlanc RA, Pesnicak L, Cabral ES, Godleski M, Straus SE: Lack of interleukin-6 (IL-6) enhances susceptibility to infection but does not alter latency or reactivation of herpes simplex virus type 1 in IL-6 knockout mice. J Virol 1999; 73:8145-8151.
47. Sin J, Kim JJ, Pachuk C, Satishchandran C, Weiner DB: DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4(+) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo. J Virol 2000; 74:11173-11180.
48. Lehrer RI, Daher K, Ganz T, Selsted ME: Direct inactivation of viruses by MCP-1 and MCP-2, natural peptide antibiotics from rabbit leukocytes. J Virol 1985; 54:467-472.
49. Kaushic C, Ashkar AA, Reid LA, Rosenthal KL: Progesterone increases susceptibility and decreases immune responses to genital herpes infection. J Virol 2003; 77:4558-4565.
50. Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, Koelle DM, Wald A, Corey L: Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proc Natl Acad Sci U S A 2010; 107:18973-18978.
51. Li H, Li X, Wei Y, Tan Y, Liu X, Wu X: HSV-2 induces TLRs and NF-kappaB-dependent cytokines in cervical epithelial cells. Biochem Biophys Res Commun 2009; 379:686-690.
52. Thomas J, Kanangat S, Rouse BT: Herpes simplex virus replication-induced expression of chemokines and proinflammatory cytokines in the eye: implications in herpetic stromal keratitis. J Interferon Cytokine Res 1998; 18:681-690.
53. Yao XD, Rosenthal KL: Herpes simplex virus type 2 virion host shutoff protein suppresses innate dsRNA antiviral pathways in human vaginal epithelial cells. J Gen Virol 2011; 92:1981-1993.
54. Rasmussen SB, Sorensen LN, Malmgaard L, Ank N, Baines JD, Chen ZJ, Paludan SR: Type I interferon production during herpes simplex virus infection is controlled by cell-type-specific viral recognition through Toll-like receptor 9, the mitochondrial antiviral signaling protein pathway, and novel recognition systems. J Virol 2007; 81:13315-13324.
55. Paludan SR, Mogensen SC: Virus-cell interactions regulating induction of tumor necrosis factor alpha production in macrophages infected with herpes simplex virus. J Virol 2001; 75:10170-10178.
56. Malmgaard L, Melchjorsen J, Bowie AG, Mogensen SC, Paludan SR: Viral activation of macrophages through TLR-dependent and -independent pathways. J Immunol 2004; 173:6890-6898.
57. Melchjorsen J, Pedersen FS, Mogensen SC, Paludan SR: Herpes simplex virus selectively induces expression of the CC chemokine RANTES/CCL5 in macrophages through a mechanism dependent on PKR and ICP0. J Virol 2002; 76:2780-2788.
58. Melchjorsen J, Siren J, Julkunen I, Paludan SR, Matikainen S: Induction of cytokine expression by herpes simplex virus in human monocyte-derived macrophages and dendritic cells is dependent on virus replication and is counteracted by ICP27 targeting NF-kappaB and IRF-3. J Gen Virol 2006; 87:1099-1108.
59. Paludan SR: Requirements for the induction of interleukin-6 by herpes simplex virus-infected leukocytes. J Virol 2001; 75:8008-8015.
60. Roth K, Ferreira VH, Kaushic C: HSV-2 vaccine: current state and insights into development of a vaccine that targets genital mucosal protection. Microb Pathog 2012; 58:45-54.
61. Bhavanam S, Snider DP, Kaushic C: Intranasal and subcutaneous immunization under the effect of estradiol leads to better protection against genital HSV-2 challenge compared to progesterone. Vaccine 2008; 26:6165-6172.
62. Roth KL, Bhavanam S, Jiang H, Gillgrass A, Ho K, Ferreira VH, Kaushic C: Delayed but effective induction of mucosal memory immune responses against genital HSV-2 in the absence of secondary lymphoid organs. Mucosal Immunol 2013; 6:56-68.
63. Keadle TL, Laycock KA, Morris JL, Leib DA, Morrison LA, Pepose JS, Stuart PM: Therapeutic vaccination with vhs(-) herpes simplex virus reduces the severity of recurrent herpetic stromal keratitis in mice. J Gen Virol 2002; 83:2361-2365.
64. Smith TJ, Morrison LA, Leib DA: Pathogenesis of herpes simplex virus type 2 virion host shutoff (vhs) mutants. J Virol 2002; 76:2054-2061.
65. Luo C, Goshima F, Kamakura M, Mutoh Y, Iwata S, Kimura H, Nishiyama Y: Immunization with a highly attenuated replication-competent herpes simplex virus type 1 mutant, HF10, protects mice from genital disease caused by herpes simplex virus type 2. Front Microbiol 2012; 3:158.